Last Updated on December 24, 2023 by The Health Master
Lupin has announced that it has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application for Chlorpromazine Hydrochloride Tablets USP, 10 mg, 25 mg, 50 mg, 100 mg, and 200 mg.
This drug approval is to market a generic equivalent to the reference listed drug (RLD), Chlorpromazine Hydrochloride Tablets USP, 10 mg, 25 mg, 50 mg, 100 mg, and 200 mg of Upsher-Smith Laboratories, LLC.
This product will be manufactured at Lupin’s Somerset facility in the U.S.
Chlorpromazine Hydrochloride Tablets USP had an estimated annual sale of USD 45 million in the U.S.
USFDA gives approval for OTC Acetaminophen and Ibuprofen Tablets
USFDA gives tentative nod for Dolutegravir tablets for oral suspension
USFDA approves 1st OTC Daily Oral Contraceptive
USFDA gives nod for Sevelamer HCL tablets
USFDA gives nod to this Nasal spray for Vitamin B12 deficiency
The importance of NABL Accreditation in international Pharma Trade for MSMEs
Pharma Industry urges Govt to authorize Private labs to test cough syrups
USFDA indicates voluntary action for Aurobindo Pharma:: AP
The Impact of Online Pharmacies on the Conventional Drug Distribution System
Drug Alert Process: Factors to Consider for Drug Regulator
Pharma company penalised Rs 45 lakh for pollution
NABL: Awareness on accreditation for Drugs and Pharma Testing Laboratories
USFDA declines to approve this Parkinson’s drug
USFDA issues Form 483 with one observation to Gland Pharma: Hyderabad
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
